Autolus Therapeutics

Christopher Vann, Chief Operating Officer

April 15 | 12:00pm | Salone dei Cavalieri, Section 2

London, United Kingdom

(NASDAQ GS: AUTL)

Autolus Therapeutics is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases.

www.autolus.com



By using this website you agree to accept our Privacy Policy and Terms & Conditions